Erratum: Phenotypic composition of salivary gland tumors: An application of principal component analysis to tissue microarray data (Modern Pathology (2004) 17 (803-810) (doi:10.1038/modpathol.3800122));Phenotypic composition of salivary gland tumors: An application of principle component analysis to tissue microarray data

Modern Pathology

Volumn 17, Issue 7, 2004, Pages 803-810

  Iwafuchi, Hideto ^a   Mori, Naoyoshi ^b   Takahashi, Takashi ^a   Yatabe, Yasushi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Component analysis; Immunohistochemical analysis; Principle; Salivary gland tumor; Tissue microarray

Indexed keywords

14 3 3SIGMA PROTEIN; CALDESMON; CALPONIN; CD44V6 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 7; CYTOKERATIN 8; MASPIN; MOLECULAR MARKER; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN P63; SMA ALPHA PROTEIN; UNCLASSIFIED DRUG;

ANATOMY; ARTICLE; BASAL CELL; BIOTECHNOLOGY; CELL DIFFERENTIATION; CELL TYPE; CONTROLLED STUDY; DATA ANALYSIS; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL CELL; MAJOR CLINICAL STUDY; MORPHOLOGY; MYOEPITHELIUM CELL; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SALIVARY GLAND TUMOR; TISSUE MICROARRAY; TUMOR CLASSIFICATION;

EID: 3042675141     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800214     Document Type: Erratum

References (38)

1. Cheuk W, Chan JKC. Salivary gland tumors. In: Fletcher CDM (ed). Diagnostic Histopathology of Tumors. Churchill Livingstone: London, 2000, pp 231-311.
2. Prasad AR, Savera AT, Gown AM, et al. The myo-epithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma. Arch Pathol Lab Med 1999;123:801-806.
3. Savera AT, Gown AM, Zarbo RJ. Immunolocalization of three novel smooth muscle-specific proteins in salivary gland pleomorphic adenoma: assessment of the morphogenetic role of myoepithelium. Mod Pathol 1997;10:1093-1100.
4. Weber A, Langhanki L, Schutz A, et al. Expression profiles of p53, p63, and p73 in benign salivary gland tumors. Virchows Arch 2002;441:428-436.
5. Ogawa Y, Toyosawa S, Ishida T, et al. Keratin 14 immunoreactive cells in pleomorphic adenomas and adenoid cystic carcinomas of salivary glands. Virchows Arch 2000;437:58-68.
6. de Araujo VC, de Sousa SO, Carvalho YR, et al. Application of immunohistochemistry to the diagnosis of salivary gland tumors. Appl Immunohistochem Mol Morphol 2000;8:195-202.
7. de Araujo VC, de Sousa SO. Expression of different keratins in salivary gland tumours. Eur J Cancer B Oral Oncol 1996;32B:14-18.
8. Bilal H, Handra-Luca A, Bertrand JC, et al. p63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues. J Histochem Cytochem 2003;51:133-139.
9. Moritani S, Kushima R, Sugihara H, et al. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002;15:397-405.
10. Fonseca I, Moura Nunes JF, Soares J. Expression of CD44 isoforms in normal salivary gland tissue: an immunohistochemical and ultrastructural study. Histochem Cell Biol 2000;114:483-488.
11. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718.
12. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-713.
13. Yang A, McKeon F. p63 and p73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000;1:199-207.
14. Hendrix MJ. De-mystifying the mechanism(s) of maspin. Nat Med 2000;6:374-376.
15. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263:526-529.
16. Sternlicht MD, Kedeshian P, Shao ZM, et al. The human myoepithelial cell is a natural tumor suppressor. Clin Cancer Res 1997;3:1949-1958.
17. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3-11.
18. Chan TA, Hermeking H, Lengauer C, et al. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-620.
19. Lopez-Girona A, Furnari B, Mondesert O, et al. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 1999;397:172-175.
20. Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol 2003;27:178-186.
21. Iwaya K, Ogawa H, Izumi M, et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002;440:589-593.
22. McCluggage WG, Sumathi VP, Maxwell P CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273-278.
23. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
24. Lipponen P, Aaltoma S, Kosma VM, et al. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998;186:157-164.
25. Soukka T, Salmi M, Joensuu H, et al. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 1997;57:2281-2289.
26. Muller W, Schneiders A, Heider KH, et al. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol 1997;183:222-227.
27. Yatabe Y, Osada H, Tatematsu Y, et al. Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential. Oncogene 2002;21:8310-8319.
28. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
29. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256.
30. Rubin MA, Dunn R, Strawderman M, et al. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26:312-319.
31. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-1251.
32. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949.
33. Yatabe Y, Mitsudomi T, Takahashi T. Maspin expression in normal lung and non-small cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene (in press).
34. Jolliffe IT. Principal Component Analysis, Springer Series in Statistics, 2nd edition. Springer: Berlin, 2002.
35. Grandi D, Campanini N, Becchi G, et al. On the myoepithelium of human salivary glands. An immunocytochemical study. Eur J Morphol 2000;38:249-255.
36. Ellis GL, Auclair PL. Tumors of the salivary glands. Atlas of Tumor Pathology, 3rd edn. Armed Force Institute of Pathology: Washington DC, 1996.
37. Seifert G, Sobin LH. Histological typing of salivary gland tumours. World Health Organization International Histological Classification of Tumours, 2nd edn. Springer: Berlin, 1991.
38. Zarbo RJ. Salivary gland neoplasia: a review for the practicing pathologist. Mod Pathol 2002;15:298-323.